Bone Marrow-Derived Stem Cells for Patients with Liver Cirrhosis: A Systematic Review and Meta-analysis
Bone Marrow-Derived Stem Cells for Patients with Liver Cirrhosis: A Systematic Review and Meta-analysis
复制标题
骨髓干细胞治疗肝硬化患者：系统评价和荟萃分析
DOI：
--
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Li Ban
中科院分区：
文献类型：
--
作者：
Shi Ouyang;Lei Ouyang;Yuanqi Li;Yaling Ye;Li Ban
背景资料：迄今为止，研究显示骨髓源性干细胞（BMDSC）治疗肝硬化患者的结果不一致。本研究旨在比较BMDSC与标准疗法治疗肝硬化的有效性和安全性。方法：从PubMed、Embase和科克伦图书馆检索自成立至2018年4月的文献。指标包括终末期肝病模型（MELD）、丙氨酸转氨酶（ALT）、白蛋白、总胆红素（TBIL）、凝血酶原时间（PT）、Child-Pugh评分和全因死亡率。结果：共纳入9篇研究，共424例肝硬化患者。BMDSC治疗与3个月内较低的MELD相关（P = .010），而6个月后对MELD无显著影响（P = .074）。BMDSC和标准治疗在3个月内（P = 0.336）和6个月后（P = 0.379）对ALT的影响were.no差异。BMDSC在3个月内（P = 0.196）和6个月后（P = 0.840）不影响白蛋白水平。BMDSC在3个月内降低了TBIL水平（P = .037），6个月后与TBIL水平无关（P = .914）。BMDSC和标准治疗之间没有差异。PT在3个月内（P = 0.167）和6个月后（P = 0.484）。3个月内（P = .342）和6个月后的Child-Pugh评分。（P = .133）与肝硬化患者的BMDSC治疗无关。最后，与标准治疗相比，BMDSC与全因死亡风险无关（P = 0.622）。结论：与标准治疗相比，BMDSC治疗肝硬化患者可改善短期MELD和TBIL，但不能降低死亡风险。
Background: To date, studies have shown inconsistent results of treatment with bone marrow-derived stem cells (BMDSC) for patients.with liver cirrhosis. This study aims to compare the efficacy and safety of BMDSC and standard therapy for liver cirrhosis..Methods: Articles from PubMed, Embase, and the Cochrane library were searched from inception to April 2018. The index included Model.for End-stage Liver Disease (MELD), alanine aminotransferase (ALT), albumin, total bilirubin (TBIL), prothrombin time (PT), Child–Pugh.score, and all-cause mortality..Results: A total of 9 studies with a total of 424 patients with liver cirrhosis were included in final meta-analysis. BMDSC therapy was.associated with lower MELD within 3 months (P = .010), while it had no significant impact on MELD after 6 months (P = .074). There were.no differences between BMDSC and standard therapy for ALT within 3 months (P = .336) and after 6 months (P = .379). BMDSC did not.affect albumin level within 3 months (P = .196) and after 6 months (P = .840). BMDSC reduced the TBIL level within 3 months (P = .037).and was not associated with the TBIL level after 6 months (P = .914). There were no differences between BMDSC and standard therapy.for PT within 3 months (P = .167) and after 6 months (P = .484). The Child–Pugh scores within 3 months (P = .342) and after 6 months.(P = .133) were not associated with BMDSC treatment for liver cirrhosis patients. Finally, the BMDSC was not associated with the risk of.all-cause mortality, as compared with standard therapy (P = .622)..Conclusions: BMDSC treatment for patients with liver cirrhosis could improve short-term MELD and TBIL, but not the risk of mortality,.as compared with standard therapy.